| The UK has one of the fastest growing and | | | | and approvals. These amendments will speed trial |
| strongest Biotech and Pharmaceuticals sectors in the | | | | start times. UK health governments have the right |
| world. The growth of this sector is driven by its rich | | | | strategies in place to make the UK the best place in |
| pool of skills and talent. A strong academic base, | | | | world for health research, innovation and |
| government support for R&D through investment | | | | development. The government has also increased its |
| and tax credits attract leading companies to the UK. | | | | funding to the sector which will reach 1.7 billion |
| The UK life sciences sector enjoys an outstanding | | | | pounds per year by 2010-2011. The world class |
| rate of success. Twenty-five of the world's 100 top | | | | scientific institutions, strong research base and |
| selling medicines were discovered and developed in | | | | outstanding record in product development are |
| the UK. | | | | attractive for investors to invest in UK's Biotech and |
| Infrastructure for the Biotech and Pharmaceuticals | | | | Pharma sector. |
| sector | | | | Chemicals and Process Industries |
| The UK offers superior educational institutions and | | | | UK chemicals and process industries have firm |
| training and research facilities that help develop and | | | | foundations due to the presence of an excellent |
| support clinical research. The UK is home to many | | | | infrastructure, extensive technical expertise, support |
| postgraduate degree granting institutes that specialize | | | | network and skills. It is one of the largest |
| in regulatory and clinical affairs. The UK has made a | | | | manufacturing sectors, accounting for 11% of total |
| major investment of more than 200 million pounds | | | | revenue from manufacturing sector. |
| recently in R&D in the UK biotech and | | | | The growth of this sector is based on core strengths |
| pharmaceuticals sector which has boosted the | | | | of science, innovation and research and development. |
| capacity and capability of early phase clinical studies | | | | The UK supports four key process and chemical |
| and experimental medicine research. | | | | industries: |
| The UK Clinical Research Network, formed in 2005, | | | | Base and Petrochemicals |
| provides a performance managed infrastructure to | | | | Fine and Specialty Chemicals |
| industry sponsored clinical trials, investigator initiated | | | | Biotechnology |
| trials, and well designed studies. This infrastructure | | | | Pharmaceuticals manufacturing |
| support is given in association with National Health | | | | UK chemicals and process industries gain advantages |
| Services. UKCRN research includes a series of topic | | | | from a range of facilities to produce sustained |
| specific and comprehensive research across the | | | | growth in the sector in the future. The chemical |
| network spread in the UK. The research covers a full | | | | industry has laid its strong foundations based on |
| range of medical conditions, including rare diseases. | | | | productive relationship between public and private |
| The UKCRN also works with biotech, pharmaceuticals | | | | sector companies, local academic institutions and |
| and devices to facilitate and streamline commercial | | | | technology driven industry experts. The 10 million |
| research, and industry sponsored trials. | | | | pound, 21st century training center, National Skills |
| Stable Regulatory environment | | | | Academy for the Process Industries provides training |
| The UK provides a balanced regulatory environment | | | | and world class opportunities to new entrants and |
| to the sector. The stable environment takes into | | | | existing workers to update and learn new skills. This |
| consideration human and environmental safety and at | | | | training facility will play an important role in creating a |
| the same time encourages innovation and | | | | new workforce for the future. The government has |
| entrepreneurial efforts. The government is taking | | | | doubled its investment in R&D which has shown |
| steps to streamline the regulatory environment which | | | | impressive results. The government also offers tax |
| includes streamlined systems for research permissions | | | | incentives in R&D to companies based in UK. |